The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PLERIXAFOR EUGIA/ PLERIXAFOR EPSL/ EUG-PLERIXAFOR (Eugia Pharma (Australia) Pty Ltd)
Product name
PLERIXAFOR EUGIA/ PLERIXAFOR EPSL/ EUG-PLERIXAFOR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
115 (175 working days)
Active ingredients
plerixafor
Registration type
New generic medicine
Indication
EUG-PLERIXAFOR is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise haematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma (MM).